1. Report Overview
1.1 Global Human Microbiome Therapeutics: Market Overview
1.2 Global Human Microbiome Therapeutics: Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who Is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. An Introduction to Human Microbiome
2.1 The Pharmaceutical Industry: A Brief Introduction
2.2 Human Microbiota in Health
2.2.1 Microbiome-Host Interaction
2.2.2 Human Microbiota Ecosystems
2.3 Human Microbiota in Disease
2.3.1 Role of Microbiota in Health and Disease (Human Microbiota in Health)
2.3.2 Effects of Probiotics and Prebiotics on gut microbiota
2.4 Microbiome Projects under development
2.5 Hindrances for Microbiome as therapy
2.6 Unmet needs of Microbiome
3. The Global Burden of Human Microbiome Diseases
4. Human Microbiome Therapeutics: Market Segmentation
4.1 Gastrointestinal Disorders
4.1.1 Classification of Gastrointestinal Disorders
4.1.2 Role of Microbiota in Gastrointestinal Disorders
4.2 Infectious Disorders
4.2.1 Classification of Infectious Disease
4.2.2 Role of Microbiota in Infectious Disease
4.3 Metabolic & Liver Disorders
4.3.1 Classification of Metabolic & Liver Disorder
4.3.2 Role of Microbiota in Metabolic Disorders
4.4 Dermatological Conditions
4.4.1 Classification of Dermatological Conditions
4.4.2 Role of Microbiota in Dermatological Conditions
5. Phases of Clinical Trials
6. Human Microbiome Therapeutics: Market Definition
6.1 The Global Human Microbiome Therapeutics Market, 2020-2030
6.2 The Global Human Microbiome Therapeutics Market: Market Overview
6.3 The Global Human Microbiome Therapeutics In 2020
6.4 The Global Human Microbiome Therapeutics Market Forecast 2020-2030
6.5 Human Microbiome Therapies: Changing Market Shares by Sector 2020-2030
7. Global Human Microbiome Therapeutics Market by Sector: Market Forecast 2020-2030
7.1 Gastrointestinal Disorders Submarket Forecast 2020-2030
7.2 Infectious Diseases Submarket Forecast 2020-2030
7.3 Metabolic Diseases Submarket Forecast 2020-2030
7.4 Dermatological Conditions Submarket Forecast 2020-2030
7.5 Other Disorders (Cardiovascular, CNS, Cancer) Submarket Forecast 2020-2030
8. Global Microbiome Therapeutics Market Potential
8.1 Microbiome Therapeutics Market Potential for GI Disorders
8.2 Microbiome Therapeutics Market Potential for Infectious Disorders
8.3 Microbiome Therapeutics Market Potential for Metabolic Disorders
8.4 Microbiome Therapeutics Market Potential for Dermatological Conditions
8.5 Microbiome Therapeutics Market Potential for Other Disorders
9. Leading National Markets for Human Microbiome Therapies: Market Forecast 2020-2030
9.1 The Human Microbiome Therapeutics Market by Region
9.1.1 Global Distribution of Human Microbiome Therapeutics, 2021
9.2 Leading National Markets: Forecast 2020-2030
9.2.1 Changing Market Shares by Region, 2020-2030
9.3 United States
9.3.1 The United States Human Microbiome Therapeutics Market: Market Forecast 2020-2030
9.3.2 The United States Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
9.3.2.1 The United States Human Microbiome Therapies: Changing Market Shares by Sector 2020-2030
9.4 EU5
9.4.1 EU5 Human Microbiome Therapeutics Market: Market Forecast 2020-2030
9.4.1.1 EU5 Markets: Changing Market Shares by Country, 2020-2030
9.4.2 EU5 Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
9.4.2.1 EU5 Human Microbiome Therapies: Changing Market Shares by Sector 2020-2030
9.5 Germany
9.5.1 German Human Microbiome Therapeutics Market: Market Forecast 2020-2030
9.5.2 German Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
9.5.2.1 German Human Microbiome Therapies: Changing Market Shares by Sector, 2020-2030
9.6 France
9.6.1 French Human Microbiome Therapeutics Market: Market Forecast 2020-2030
9.6.2 French Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
9.6.2.1 French Human Microbiome Therapies: Changing Market Shares by Sector, 2020-2030
9.7 UK
9.7.1 UK Human Microbiome Therapeutics Market: Market Forecast 2020-2030
9.7.2 UK Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
9.7.2.1 UK Human Microbiome Therapies: Changing Market Shares by Sector, 2020-2030
9.8 Italy
9.8.1 Italian Human Microbiome Therapeutics Market: Market Forecast 2020-2030
9.8.2 Italian Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
9.8.2.1 Italian Human Microbiome Therapies: Changing Market Shares by Sector, 2020-2030
9.9 Spain
9.9.1 Spanish Human Microbiome Therapeutics Market: Market Forecast 2020-2030
9.9.2 Spanish Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
9.9.2.1 Spanish Human Microbiome Therapies: Changing Market Shares by Sector, 2020-2030
9.10 APAC
9.10.1 APAC Human Microbiome Therapeutics Market: Market Forecast 2020-2030
9.10.1.1 APAC Markets: Changing Market Shares by Country, 2020-2030
9.10.2 APAC Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
9.10.2.1 APAC Human Microbiome Therapies: Changing Market Shares by Sector 2020-2030
9.11 Japan
9.11.1 The Cost of Treatment in Japan
9.11.2 Japanese Pharmaceutical Industry Regulatory Reform
9.11.3 Japanese Human Microbiome Therapeutics Market Forecast 2020-2030
9.11.4 Japan Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
9.11.4.1 Japan Human Microbiome Therapies: Changing Market Shares by Sector, 2020-2030
9.12 Rest of the World
9.12.1 Rest of the World Human Microbiome Therapeutics Market: Market Forecast 2020-2030
10. Deals in Human Health Therapeutics by Year
11. Leading Companies in the Human Microbiome Therapeutics Market, 2020-2030
11.1 4D Pharma Plc.
11.1.1 4D Pharma: Collaborations and Acquisitions
11.1.2 4D Pharma: Microbiome Drugs Development Pipeline, 2019
11.1.3 4D Pharma: Recent Developments
11.1.4 4D Pharma: Key Pipeline Products
11.2 Synthetic Biologics
11.2.1 Synthetic Biologics: Collaborations and Agreement
11.2.2 Synthetic Biologics: Drug Development Pipeline, 2019
11.2.3 Synthetic Biologics: Recent Developments
11.2.4 Synthetic Biologics Key Pipeline Products,2019
11.3 Seres Therapeutics
11.3.1 Seres Therapeutics: Collaborations and Agreement
11.3.2 Seres Therapeutics: Drug Development Pipeline, 2019
11.3.3 Seres Therapeutics: Key Pipeline Products
11.4 Ferring Pharmaceuticals
11.4.1 Ferring Pharmaceuticals: Collaborations and Agreement
11.4.2 Ferring Pharmaceuticals: Drug Development Pipeline, 2019
11.4.3 Ferring Pharmaceuticals: Key Pipeline Products, 2019
11.5 AOBiome Therapeutics
11.5.1 AOBiome Therapeutics: Collaborations and Agreement
11.5.2 AOBiome Therapeutics: Drug Development Pipeline, 2019
11.5.3. AOBiome Therapeutics: Key Pipeline Products, 2019
11.6 Osel Inc.
11.6.1 Osel Inc: Product Development Activities
11.6.2 Osel Inc: Drug Development Pipeline, 2019
11.6.3 Osel Inc: Key Pipeline Products, 2019
11.7 Immuron Ltd
11.7.1 Immuron: Collaboration and Agreement
11.7.2 Immuron: Drug Development Pipeline, 2019
11.7.3 Immuron: Key Pipeline Products, 2019
11.8 Ritter Pharmaceuticals, Inc.
11.8.1 Ritter Pharmaceuticals: Collaboration and Agreement
11.8.2 Ritter Pharmaceuticals: Drug Development Pipeline, 2019
11.8.3 Ritter Pharmaceuticals: Key Pipeline Products, 2019
11.9 Intrexon Corporation
11.9.1 Intrexon: Collaboration and Agreement
11.9.2 Intrexon: Drug Development Pipeline, 2019
11.9.3 Intrexon: Key Pipeline Products, 2019
11.10 Synlogic
11.10.1 Synlogic: Collaborations and Agreement
11.10.2 Synlogic: Drug Development Pipeline, 2019
11.10.3 Synlogic: Key Pipeline Products, 2019
11.11 C3J Therapeutics
11.11.1 C3J Therapeutics: Product Development Activities
11.11.2 C3J Therapeutics: Drug Development Pipeline, 2019
11.11.3 C3J Therapeutics: Key Pipeline Products, 2019
11.12 Finch Therapeutics/Crestovo
11.12.1 Finch/Crestovo: Collaboration and Agreement
11.12.2 Finch/Crestovo: Drug Development Pipeline, 2019
11.12.3 Finch/Crestovo: Key Pipeline Products, 2019
11.13 MaaT Pharma
11.13.1 MaaT Pharma: Collaboration and Agreement
11.13.2 MaaT Pharma: Drug Development Pipeline, 2019
11.14 IGEN BIOTECH GROUP
11.14.1 IGEN BIOTECH: Product Development Activities
11.14.2 IGEN BIOTECH: Key Pipeline Products
11.15 MatriSys Biosystem
11.15.1 MatriSys Biosystem: Product Development Activities
11.15.2 MatriSys Biosystem: Drug Development Pipeline, 2019
11.15.3 MatriSys Biosystem: Key Pipeline Products, 2019
11.16 Second Genome
11.16.1 Second Genome: Collaboration and Agreement
11.16.2 Second Genome: Drug Development Pipeline, 2019
11.16.3 Second Genome: Key Pipeline Products, 2019
11.17 Microbiome Therapeutics LLC
11.17.1 Microbiome Therapeutics: Product Development Activities
11.17.2 Microbiome Therapeutics: Drug Development Pipeline, 2019
11.17.3 Microbiome Therapeutics: Key Pipeline Products, 2019
11.18 Caelus Health
11.18.1 Caelus Health: Collaboration and Agreement
11.18.2 Caelus Health: Drug Development Pipeline, 2019
11.18.3 Caelus Health: Key Pipeline Products, 2019
11.19 Enterome Bioscience
11.19.1 Enterome Bioscience: Drug Development Pipeline, 2019
11.19.2 Enterome Bioscience: Collaboration and Agreement
11.19.3 Enterome Bioscience: Key Pipeline Products, 2019
11.20 Vedanta Biosciences
11.20.1 Vedanta Biosciences: Collaboration and Agreement
11.20.2 Vedanta Biosciences: Drug Development Pipeline, 2019
11.20.3 Vedanta Biosciences: Key Pipeline Products, 2019
11.21 Symberix
11.21.1 Symberix: Collaboration and Agreement
11.21.2 Symberix: Drug Development Pipeline, 2019
11.21.3 Symberix: Key Pipeline Products, 2019
11.22 Quorum Innovations
11.22.1 Quorum Innovations: Recent News
11.22.2 Quorum Innovations: Drug Development Pipeline, 2019
11.22.3 Quorum Innovations: Key Pipeline Products, 2019
11.23 Assembly Biosciences
11.23.1 Assembly Biosciences: Collaboration and Aggreement
11.23.2 Assembly Biosciences: Drug Development Pipeline,2019
11.23.3 Assembly Biosciences: Key Pipeline Products, 2019
11.24 Evelo Biosciences, Inc.
11.24.1 Evelo Biosciences, Inc.: Collaboration & Agreement
11.24.2 Evelo Biosciences, Inc.: Drug Development Pipeline, 2019
11.24.3 Evelo Biosciences, Inc.: Key Pipeline Products, 2019
11.25 LOCUS BIOSCIENCES, INC.
11.25.1 LOCUS BIOSCIENCES, INC.: Collabration & Agreement
11.25.2 LOCUS BIOSCIENCES, INC.: Drug Development Pipeline, 2019
11.25.3 LOCUS BIOSCIENCES, INC.: Key Pipeline Products, 2019
11.26 ImmuneBiotech
11.26.1 ImmuneBiotech: Collaboration & Agreement
11.26.2 ImmuneBiotech: Drug Development Pipeline, 2019
11.26.3 ImmuneBiotech: Key Pipeline Products, 2019
11.27 LNC Therapeutics
11.27.1 LNC Therapeutics: Collaboration & Agreement
11.27.2 LNC Therapeutics: Drug Development Pipeline, 2019
11.27.3 LNC Therapeutics: Key Pipeline Products, 2019
11.28 BiomX
11.28.1 BiomX: Collaboration & Agreement
11.28.2 BiomX: Drug Development Pipeline, 2019
11.28.3 BiomX: Key Pipeline Products, 2019
11.29 Symbiotix Biotherapies, Inc.
11.29.1 Symbiotix Biotherapies, Inc.: Collaboration & Agreement
11.29.2 Symbiotix Biotherapies, Inc.: Drug Development Pipeline, 2019
11.29.3 Symbiotix Biotherapies, Inc.: Key Pipeline Products, 2019
11.30 LEADING BIOSCIENCES INC.
11.30.1 LEADING BIOSCIENCES INC.: Drug Development Pipeline, 2019
11.30.2 LEADING BIOSCIENCES INC.: Key Pipeline Products, 2019
11.31 Azitra
11.31.1 Azitra: Recent News
11.31.2 Azitra: Drug Development Pipeline, 2019
11.31.3 Azitra: Key Pipeline Products, 2019
11.32 Rebiotix Inc.
11.32.1 Rebiotix Inc.: Recent News
11.32.2 Rebiotix Inc.: Drug Development Pipeline, 2019
11.32.3 Rebiotix Inc.: Key Pipeline Products, 2019
12. Gastrointestinal Disorders: Key Products, 2019
12.1 RBX2600 & RBX7455: Ferring Pharmaceuticals
12.2 SER-109, SER287 & SER-262: Seres Therapeutics
12.3 Ribaxamase & SYN-010: Synthetic Biologics
12.4 IMM-529: Immuron
12.5 SGM-1019: Second Genome
12.6 Blautix, Thetanix & Rosburix: 4D Pharma
12.7 EB8018: Enterome Bioscience
13. Metabolic Disorders: Key Products, 2019
13.1 RP-G28: Ritter Pharmaceuticals
13.2 IMM-124E: Immuron
13.3 CP-001: Caelus Health
13.4 NM504 & NM505: Microbiome Therapeutics
13.5 SYNB1020: Synlogic
14. Infectious Diseases: Key Products, 2019
14.1 LACTIN-V: Osel
14.2 AOB-201: AOBiome Therapeutics
14.3 MaaT001: MaaT Pharma
14.4 CBM588: Osel Inc.
15. Dermatological Disorders: Key Products, 2019
15.1 AOB101, AOB102 & AOB103: AOBiome Therapeutics
15.2 MSB-01 & MSB-03: MatriSys Biosystem
16. Other Disorders: Key Products, 2019
16.1 AG013: Intrexon
16.2 AOB202 & AOB 203: AOBiome Therapeutics
16.3 C16G2: C3J Therapeutics
16.4 Microbiome Modulators: IGEN BIOTECH
17. Qualitative Analysis of the Human Microbiome Therapeutics, 2020-2030
17.1 Market Factors Influencing Human Microbiome Therapeutics Market
17.2 SWOT Analysis of the Global Human Microbiome Therapeutics Market, 2020-2030
17.2.1 Strengths
17.2.1.1 Novel & Efficient Therapies
17.2.1.2 A Healthy R&D Pipeline
17.2.1.3 Collaboration Among Key Industry Players
17.2.2 Weaknesses
17.2.2.1 Market Competition
17.2.2.2 Consumer Perception
17.2.2.3 Ethical Issues
17.2.2.4 R&D Capabilities
17.2.2.5 Knowledge Gaps
17.2.3 Opportunities
17.2.3.1 Growing Patient Pool
17.2.3.2 Unmet Clinical Needs in Several Disease Areas
17.2.3.3 Label Expansion
17.2.3.4 Economic Growth in Emerging Market Provide Opportunity for Expansion
17.2.4 Threats
17.2.4.1 Capital Intensive Research
17.2.4.2 Regulatory Approval
17.2.4.3 Price
17.2.4.4 Intellectual Property
18. Conclusions
18.1 Overview of Current Market Conditions and Market Forecast, 2020-2030
18.2 Leading Sectors in Human Microbiome Therapeutics in 2020
18.3 Leading Regions in the Human Microbiome Therapeutics Market in 2020
18.4 What Does the Future Hold for Microbiome Therapeutics?
Appendices
Glossary
Associated Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form
List of Table
Table 4.1 Skin Disease and Related Microbiota
Table 5.1 Clinical Trial Phases
Table 6.1 Global Human Microbiome Therapeutics Market: Revenue ($m) and Market Share (%) by Sector, 2020
Table 6.2 Global Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
Table 6.3 Global Human Microbiome Therapeutics Market Forecast: CAGR (%) by Sector
Table 6.4 Global Human Microbiome Therapeutics Market: Revenue ($m) and Market Share (%) by Sector, 2020, 2024, 2030
Table 7.1 Global Human Microbiome Therapeutics Market for Gastrointestinal Disorders: Market Forecast ($m, AGR% and CAGR%), 2020-2030
Table 7.2 Global Human Microbiome Therapeutics Market for Infectious Diseases: Market
Forecast ($m, AGR% and CAGR%), 2020-2030
Table 7.3 Global Human Microbiome Therapeutics Market for Metabolic Diseases: Market
Forecast ($m, AGR% and CAGR%), 2020-2030
Table 7.4 Global Human Microbiome Therapeutics Market for Dermatological Conditions:
Market Forecast ($m, AGR% and CAGR%), 2020-2030
Table 7.5 Global Human Microbiome Therapeutics Market for Other Disorders: Market
Forecast ($m, AGR% and CAGR%), 2020-2030
Table 9.1 Global Human Microbiome Therapeutics Market: Market Size ($m) and Market Share (%) by Region, 2021
Table 9.2 Global Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Region, 2020-2030
Table 9.3 Global Human Microbiome Therapeutics Market Forecast: CAGR (%) by Region
Table 9.4 Global Human Microbiome Therapeutics Market Forecast: Market Share (%) by Region, 2021, 2024, and 2030
Table 9.5 The US Human Microbiome Therapeutics Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2020-2030
Table 9.6 US Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), 2020-2030
Table 9.7 The United States Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
Table 9.8 The United States Human Microbiome Therapeutics Market: Revenue ($m) and Market Share (%) by Sector, 2021, 2024, 2030
Table 9.9 EU5 Human Microbiome Drugs Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2020-2030
Table 9.10 EU5 Human Microbiome Drugs Market: Revenue ($m), and Market Share (%) by Country, 2021
Table 9.11 EU5 Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), by Country, 2020-2030
Table 9.12 EU5 Human Microbiome Therapeutics Market: Market Share (%) by Country, 2021, 2024, 2030
Table 9.13 EU5 Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
Table 9.14 EU5 Human Microbiome Therapeutics Market: Revenue ($m) and Market Share (%) by Sector, 2021, 2024, 2030
Table 9.15 German Human Microbiome Therapeutics Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2021-2030
Table 9.16 German Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), 2020-2030
Table 9.17 German Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
Table 9.18 German Human Microbiome Therapeutics Market: Revenue ($m) and Market Share (%) by Sector, 2021, 2024, 2030
Table 9.19 The French Human Microbiome Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2020-2030
Table 9.20 French Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), 2020-2030
Table 9.21 French Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
Table 9.22 French Human Microbiome Therapeutics Market: Revenue ($m) and Market Share (%) by Sector, 2021, 2024, 2030
Table 9.23 The UK Human Microbiome Therapeutics Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2020-2030
Table 9.24 UK Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), 2020-2030
Table 9.25 UK Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
Table 9.26 UK Human Microbiome Therapeutics Market: Revenue ($m) and Market Share (%) by Sector, 2021, 2024, 2030
Table 9.27 Italian Human Microbiome Therapeutics Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2020-2030
Table 9.28 Italian Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), 2020-2030
Table 9.29 Italian Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
Table 9.30 Italian Human Microbiome Therapeutics Market: Revenue ($m) and Market Share (%) by Sector, 2021, 2024, 2030
Table 9.31 Spanish Human Microbiome Therapeutics Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2020-2030
Table 9.32 Spanish Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), 2020-2030
Table 9.33 Spanish Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
Table 9.34 Spanish Human Microbiome Therapeutics Market: Revenue ($m) and Market Share (%) by Sector, 2021, 2024, 2030
Table 9.35 APAC Human Microbiome Drugs Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2020-2030
Table 9.36 EU5 Human Microbiome Drugs Market: Revenue ($m), and Market Share (%) by Country, 2021
Table 9.37 APAC Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), by Country, 2020-2030
Table 9.38 APAC Human Microbiome Therapeutics Market: Market Share (%) by Country, 2021, 2024, 2030
Table 9.39 APAC Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
Table 9.40 APAC Human Microbiome Therapeutics Market: Revenue ($m) and Market Share (%) by Sector, 2021, 2024, 2030
Table 9.41 Japanese Human Microbiome Therapeutics Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2020-2030
Table 9.42 Japanese Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), 2020-2030
Table 9.43 Japan Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
Table 9.44 Japan Human Microbiome Therapeutics Market: Revenue ($m) and Market Share (%) by Sector, 2021, 2024, 2030
Table 9.45 The Rest of the World Human Microbiome Therapeutics Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2020-2030
Table 9.46 Rest of the World Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), 2020-2030
Table 10.1 Deals Human Health Therapeutics, 2017
Table 11.1 Pipeline Therapeutics by Companies
Table 11.2 4D Pharma: Company Overview, 2019
Table 11.3 4D Pharma: Key Pipeline Products, 2019
Table 11.4 Synthetic Biologics: Company Overview, 2019
Table 11.5 Synthetic Biologics: Key Pipeline Products, 2019
Table 11.6 Seres Therapeutics: Company Overview, 2019
Table 11.7 Clinical Trials Description
Table 11.8: Clinical Trials Description
Table 11.9 Clinical Trials Description
Table 11.10 Seres Therapeutics: Key Pipeline Products, 2019
Table 11.11 Ferring Pharmaceuticals: Company Overview, 2019
Table 11.12 Clinical Trials Description
Table 11.13 Clinical Trials Description
Table 11.14 Ferring Pharmaceuticals: Key Pipeline Products, 2019
Table 11.15 AOBiome, LLC: Company Overview, 2019
Table 11.16 Clinical Trials Description
Table 11.17 AOBiome Therapeutics: Key Pipeline Products, 2019
Table 11.18 Osel Inc: Company Overview, 2019
Table 11.19 Clinical Trials Description
Table 11.20 Osel Inc: Key Pipeline Products, 2019
Table 11.21 Immuron Ltd: Company Overview, 2019
Table 11.22 Clinical Trials Description
Table 11.23 Clinical Trials Description
Table 11.24 Key Pipeline Products, 2019
Table 11.25 Ritter Pharmaceuticals, Inc.: Company Overview, 2019
Table 11.26 Clinical Trials Description
Table 11.27 Ritter Pharmaceuticals: Key Pipeline Products, 2019
Table 11.28 Intrexon Corporation: Company Overview, 2019
Table 11.29 Clinical Trials Description
Table 11.30 Intrexon: Key Pipeline Products, 2019
Table 11.31 Synlogic: Company Overview, 2019
Table 11.32 Synlogic: Key Pipeline Products, 2019
Table 11.33 C3J Therapeutics: Company Overview, 2019
Table 11.34 Clinical Trials Description
Table 11.35 C3J Therapeutics: Key Pipeline Products, 2019
Table 11.36 Finch Therapeutics: Company Overview, 2019
Table 11.37 Clinical Trials Description
Table 11.38 Finch/Crestovo: Key Pipeline Products, 2019
Table 11.39 MaaT Pharma: Company Overview, 2019
Table 11.40 Clinical Trials Description
Table 11.41 IGEN BIOTECH GROUP: Company Overview, 2019
Table 11.42 IGEN BIOTECH: Key Pipeline Products
Table 11.43 MatriSys Biosystem: Company Overview, 2019
Table 11.44 MatriSys Biosystem: Key Pipeline Products, 2019
Table 11.45 Second Genome: Company Overview, 2019
Table 11.46 Second Genome: Key Pipeline Products, 2019
Table 11.47 Microbiome Therapeutics: Company Overview, 2019
Table 11.48 Clinical Trials Description
Table 11.49 Microbiome Therapeutics: Key Pipeline Products, 2019
Table 11.50 Caelus Health: Company Overview, 2019
Table 11.51 Key Pipeline Products, 2019
Table 11.52 Enterome Bioscience: Company Overview, 2019
Table 11.53 Clinical Trials Description
Table 11.54 Enterome Bioscience: Key Pipeline Products, 2019
Table 11.55 Vedanta Biosciences: Company Overview, 2019
Table 11.56 Vedanta Biosciences: Key Pipeline Products, 2019
Table 11.57 Symberix: Company Overview, 2019
Table 11.58 Key Pipeline Products, 2019
Table 11.59 Quorum Innovations: Company Overview, 2019
Table 11.60 Key Pipeline Products, 2019
Table 11.61 Assembly Biosciences: Company Overview, 2019
Table 11.62 Key Pipeline Products, 2019
Table 11.63 Evelo Biosciences, Inc.: Company Overview, 2019
Table 11.64 Key Pipeline Products, 2019
Table 11.65 LOCUS BIOSCIENCES, INC.: Company Overview, 2019
Table 11.66 Key Pipeline Products, 2019
Table 11.67 ImmuneBiotech: Company Overview, 2019
Table 11.68 Key Pipeline Products, 2019
Table 11.69 LNC Therapeutics: Company Overview, 2019
Table 11.70 Key Pipeline Products, 2019
Table 11.71 BiomX: Company Overview, 2019
Table 11.72 Key Pipeline Products, 2019
Table 11.73 Symbiotix Biotherapies, Inc.: Company Overview, 2019
Table 11.74 Key Pipeline Products, 2019
Table 11.75 LEADING BIOSCIENCES INC.: Company Overview, 2019
Table 11.76 Key Pipeline Products, 2019
Table 11.76 Azitra: Company Overview, 2019
Table 11.76 Key Pipeline Products, 2019
Table 11.77 Rebiotix Inc.: Company Overview, 2019
Table 11.78 Key Pipeline Products, 2019
Table 12.1 Gastrointestinal Disorders Drugs Pipeline: Key Drugs, 2019
Table 13.1 Metabolic Disorders Drugs Pipeline, 2019
Table 14.1 Infectious Disease Drugs Pipeline: Key Products, 2019
Table 15.1 Dermatological Disorders Drugs Pipeline: Key Products, 2019
Table 16.1 Other Disorders Drugs Pipeline: Key Products, 2019
Table 17.2 World 65+ Population Forecast: Size (m), AGR (%), CAGR (%), 2017-2028
Table 18.1 Global Human Microbiome Therapeutics: Market Forecast ($m, CAGR%), 2020, 2024 and 2030
Table 18.2 The Global Human Microbiome Therapeutics Market: Market Forecast ($m) by Region, 2020, 2024, 2030
List of Figure
Figure 1.1 Global Human Microbiome Therapeutics Market: Market Sectors
Figure 2.1 Role of Human Microbiota in Various Diseases
Figure 6.1 Global Human Microbiome Therapeutics Market: Revenue ($m) by Sector, 2020
Figure 6.2 Global Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%), 2020-2030
Figure 6.3 Global Human Microbiome Therapeutics Market Forecast: CAGR (%) by Sector, 2024-2030
Figure 6.4 Global Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2020
Figure 6.5 Global Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2024
Figure 6.6 Global Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2030
Figure 7.1 Global Human Microbiome Therapeutics Market for Gastrointestinal Disorders: Market Forecast ($m), 2020-2030
Figure 7.2 Global Human Microbiome Therapeutics Market for Infectious Diseases: Market Forecast ($m), 2020-2030
Figure 7.3 Global Human Microbiome Therapeutics Market for Metabolic Diseases: Market Forecast ($m), 2020-2030
Figure 7.4 Global Human Microbiome Therapeutics Market for Dermatological Conditions: Market Forecast ($m), 2020-2030
Figure 7.5 Global Human Microbiome Therapeutics Market for Other Disorders: Market Forecast ($m), 2020-2030
Figure 9.1 Global Human Microbiome Therapeutics Market: Market Size ($m) by Region, 2021
Figure 9.2 US, EU, APAC and ROW Human Microbiome Therapeutics Market: Market Forecast ($m), 2020-2030
Figure 9.3 Global Human Microbiome Therapeutics Market Forecast: CAGR (%) by Region, 2021-2024
Figure 9.4 Global Human Microbiome Therapeutics Market Forecast: CAGR (%) by Region, 2024-2030
Figure 9.5 Global Human Microbiome Therapeutics Market Forecast: CAGR (%) by Region, 2021-2030
Figure 9.6 Global Human Microbiome Therapeutics Market Forecast: Market Share (%) by Region, 2021
Figure 9.7 Global Human Microbiome Therapeutics Market Forecast: Market Share (%) by Region, 2024
Figure 9.8 Global Human Microbiome Therapeutics Market Forecast: Market Share (%) by Region, 2030
Figure 9.9 US Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%), 2020-2030
Figure 9.10 The United States Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
Figure 9.11 The United States Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2021
Figure 9.12 The United States Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2024
Figure 9.13 The United States Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2030
Figure 9.14 EU5 Human Microbiome Drugs Market: Revenue ($m) by Country, 2021
Figure 9.15 Germany, France, UK, Italy, and Spain Human Microbiome Drugs Market: Market Forecast ($m), 2020-2030
Figure 9.16 EU5 Human Microbiome Therapeutics Market: Market Share (%) by Country, 2021
Figure 9.17 The EU5 Human Microbiome Therapeutics Market: Market Share (%) by Country, 2024
Figure 9.18 The EU5 Human Microbiome Therapeutics Market: Market Share (%) by Country, 2030
Figure 9.19 EU5 Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
Figure 9.20 EU5 Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2021
Figure 9.21 EU5 Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2024
Figure 9.22 EU5 Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2030
Figure 9.23 German Human Microbiome Therapeutics Market: Market Forecast ($m), 2020-2030
Figure 9.24 German Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
Figure 9.25 German Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2021
Figure 9.26 German Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2024
Figure 9.27 German Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2030
Figure 9.28 French Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%), 2020-2030
Figure 9.29 French Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
Figure 9.30 French Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2021
Figure 9.31 French Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2024
Figure 9.32 French Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2030
Figure 9.33 UK Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%), 2020-2030
Figure 9.34 UK Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
Figure 9.35 UK Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2021
Figure 9.36 UK Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2024
Figure 9.37 UK Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2030
Figure 9.38 Italian Human Therapeutics Market: Market Forecast ($m, AGR%), 2020-2030
Figure 9.39 Italian Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
Figure 9.40 Italian Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2021
Figure 9.41 Italian Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2024
Figure 9.42 Italian Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2030
Figure 9.43 Spanish Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%), 2020-2030
Figure 9.44 Spanish Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
Figure 9.45 Spanish Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2021
Figure 9.46 Spanish Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2024
Figure 9.47 Spanish Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2030
Figure 9.48 APAC Human Microbiome Drugs Market: Revenue ($m) by Country, 2021
Figure 9.49 Japan, China, India, Australia, Korea and Others Human Microbiome Drugs Market: Market Forecast ($m), 2020-2030
Figure 9.50 APAC Human Microbiome Therapeutics Market: Market Share (%) by Country, 2021
Figure 9.51 APAC Human Microbiome Therapeutics Market: Market Share (%) by Country, 2024
Figure 9.52 APAC Human Microbiome Therapeutics Market: Market Share (%) by Country, 2030
Figure 9.53 APAC Human Microbiome Therapeutics Market: Market Forecast ($m) by Sector, 2020-2030
Figure 9.54 APAC Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2021
Figure 9.55 APAC Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2024
Figure 9.56 APAC Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2030
Figure 9.57 Japanese Human Microbiome Therapeutics Market: Market Forecast ($m), 2020-2030
Figure 9.58 Japan Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2020-2030
Figure 9.59 Japan Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2024
Figure 9.60 Japan Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2030
Figure 9.32 Rest of the World Human Microbiome Therapeutics Market: Market Forecast ($m), 2020-2030
Figure 11.1 Enterome Bioscience
Figure 11.2 Evelo Biosciences, Inc.
Figure 18.1 Global Human Microbiome Therapeutics: Market Forecast ($m), 2020- 2030
Figure 18.2 The Global Human Microbiome Therapeutics Market: Market Forecast ($m) by Region, 2020-2030
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
